Trial Profile

A phase II placebo controlled investigator initiated trial of RS5614 for treatment of Novel corona virus lung injury

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Feb 2024 According to a Renascience media release, the trial was conducted in collaboration with 20 universities and other major medical institutions in Japan including Tohoku University, Kyoto University, Tokyo Medical and Dental University, and Tokai University. The trial started in June 2021 after the implementation plan was finalized based on a preliminary meeting with the Pharmaceuticals and Medical Devices Agency in April 2021, the trial was extended until the end of October 2022.
22 Feb 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com